Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area of increasing interest. Multiple methods have been proposed but few studies have compared the performance of different approaches. Here, we compare detection of ctDNA in serial plasma samples from patients with breast cancer using different tumor-informed and tumor-naïve assays designed to detect structural variants (SVs), single nucleotide variants (SNVs), and/or somatic copy-number aberrations, by multiplex PCR, hybrid capture, and different depths of whole-genome sequencing. Our results demonstrate that the ctDNA dynamics and allele fractions (AFs) were highly concordant when analyzing the same patient samples using different assays. Tumor-informed assays showed the highest sensitivity for detection of ctDNA at low concentrations. Hybrid capture sequencing targeting between 1,347 and 7,491 tumor-identified mutations at high depth was the most sensitive assay, detecting ctDNA down to an AF of 0.00024% (2.4 parts per million, ppm). Multiplex PCR targeting 21-47 tumor-identified SVs per patient detected ctDNA down to 0.00047% AF (4.7 ppm) and has potential as a clinical assay.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tumor-informed assays, based on the mutations existing in the tumor tissue, enable deep sequencing targeting known mutations and MRD detection, which has been validated across multiple solid tumors.19, 20, 21”
From Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma (2024) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434 · cited 2×
“Variants present within the gnomAD germline resource (Karczewski et al, 2020) or in a pooled panel of normals (compiled by calling germline variants from WGS data derived from buffy coat of a cohort of 200 breast cancer patients) were removed.”
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480 · cited 1×
“Primers were preferentially selected in non-repetitive regions with unique BLAT hits (https://genome.ucsc.edu) (Kent, 2002).”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067 · cited 2×
“Chromosomal rearrangements are often clonal, formed in early tumor development and “passenger” mutations, not subject to positive or negative selection pressures (Wang et al, 2014).”
circlize implements and enhances circular visualization in R
Gu, Z., Gu, L., Eils, R., Schlesner, M., & Brors, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu393 · Cited by 4,246
SeqKit: A Cross-Platform and Ultrafast Toolkit for FASTA/Q File Manipulation
Shen, W., Le, S., Li, Y., & Hu, F. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163962 · Cited by 3,380 · cited 1×
“The UMI was concatenated with read 1 and read 2 using Seqkit v.0.10.1 (Shen et al, 2016).”
InfluentialLiquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · cited 2×
“In patients with low burden disease, the detection of ctDNA when only a few tumor-derived molecules may be present in blood can be challenging and is often limited by stochastic sampling (Wan et al, 2017).”
Self-citationDetection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783 · cited 1×
“…research is required to improve the sensitivity of tumor-naïve assays to the required levels of sensitivity, through incorporation of additional features or biomarkers (Cohen et al, 2018), as this would have obvious benefits to optimize treatment regimes in patients with earlier stage disease.”
Primer3Plus, an enhanced web interface to Primer3
Untergasser, A., Nijveen, H., Rao, X., Bisseling, T., Geurts, R., & Leunissen, J. A. M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm306 · Cited by 2,779
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
(2015) · doi:10.1093/bioinformatics/btv710 · Cited by 2,234
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220 · cited 1×
“…of the total circulating cell-free DNA. ctDNA levels can vary in different cancer types, and higher fractional concentrations of ctDNA in plasma have been associated with larger tumor volume and more advanced disease stage (Bettegowda et al, 2014; Newman et al, 2014; Parkinson et al, 2016).”
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2019) · doi:10.1101/531210 · Cited by 1,662
Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs
Saunders, C. T., Wong, W. S. W., Swamy, S., Becq, J., Murray, L. J., & Cheetham, R. K. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts271 · Cited by 1,635
Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C., Seiden, M. V., Liu, M. C., Oxnard, G. R., Klein, E. A., Smith, D., Richards, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.011 · Cited by 1,495 · cited 2×
“Additional studies have used epigenetic analysis to profile differentially methylated regions in cell-free DNA and identify the tissue of origin (Shen et al, 2019; Liu et al, 2020; Sadeh et al, 2021).”
InfluentialForshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D. W. Y., Kaper, F., Dawson, S.-J., Piskorz, A. M., Jimenez-Linan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,297
Self-citationMutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., Cheang, M., Osin, P., Nerurkar, A., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,150
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3520 · Cited by 1,099
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Tie, J., Cohen, J. D., Lahouel, K., Lo, S. N., Wang, Y., Kosmider, S., Wong, R., Shapiro, J., Lee, M., Harris, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200075 · Cited by 1,091 · cited 1×
“…patient-specific assays to identify patients at high risk of relapse, who may benefit from adjuvant therapy, or to de-escalate treatment in patients with no residual ctDNA detected post-treatment, thereby avoiding unnecessary side-effects (Abbosh et al, 2017; Gale et al, 2022; Tie et al, 2022).”
Enhanced detection of circulating tumor DNA by fragment size analysis
Mouliere, F., Chandrananda, D., Piskorz, A. M., Moore, E. K., Morris, J., Ahlborn, L. B., Mair, R., Goranova, T., Marass, F., Heider, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat4921 · Cited by 1,069
Self-citationScalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Adalsteinsson, V. A., Ha, G., Freeman, S. S., Choudhury, A. D., Stover, D. G., Parsons, H. A., Gydush, G., Reed, S. C., Rotem, D., Rhoades, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00965-y · Cited by 1,051
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
Wang, Y., Waters, J., Leung, M. L., Unruh, A., Roh, W., Shi, X., Chen, K., Scheet, P., Vattathil, S., Liang, H., et al. (2014) · Nature · doi:10.1038/nature13600 · Cited by 1,029
Application of Cell-free DNA Analysis to Cancer Treatment
Corcoran, R. B., & Chabner, B. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706174 · Cited by 950
Patterns of somatic structural variation in human cancer genomes
Li, Y., Roberts, N. D., Wala, J. A., Shapira, O., Schumacher, S. E., Kumar, K., Khurana, E., Waszak, S., Korbel, J. O., Haber, J. E., et al. (2020) · Nature · doi:10.1038/s41586-019-1913-9 · Cited by 867 · cited 1×
“However, identifying SVs remains a challenge and there are much fewer events in the genome compared to SNVs (Li et al, 2020).”
Self-citationLanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695 · cited 1×
“…been developed which target disease-specific structural rearrangements such as ALK and ROS1 gene fusions, which have enabled non-small cell lung cancer (NSCLC) patients harboring these mutations to be effectively treated with tyrosine kinase inhibitors (Lanman et al, 2015; Plagnol et al, 2018).”
Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies
Lo, Y. M. D., Han, D. S. C., Jiang, P., & Chiu, R. W. K. (2021) · Science · doi:10.1126/science.aaw3616 · Cited by 662
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
Leary, R. J., Kinde, I., Diehl, F., Schmidt, K., Clouser, C., Duncan, C., Antipova, A., Lee, C., McKernan, K., De La Vega, F. M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000702 · Cited by 517
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S., Ali, S., Cleator, S., Kenny, L., Stebbing, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3663 · Cited by 510
Thress, K. S., Brant, R., Carr, T. H., Dearden, S., Jenkins, S., Brown, H., Hammett, T., Cantarini, M., & Barrett, J. C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.004 · Cited by 493
Detection and characterization of lung cancer using cell-free DNA fragmentomes
Mathios, D., Johansen, J. S., Cristiano, S., Medina, J. E., Phallen, J., Larsen, K. R., Bruhm, D. C., Niknafs, N., Ferreira, L., Adleff, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24994-w · Cited by 472
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
Magbanua, M. J. M., Swigart, L. B., Wu, H.-T., Hirst, G. L., Yau, C., Wolf, D. M., Tin, A., Salari, R., Shchegrova, S., Pawar, H., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.007 · Cited by 462
Olsson, E., Winter, C., George, A., Chen, Y., Howlin, J., Tang, M. E., Dahlgren, M., Schulz, R., Grabau, D., van Westen, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404913 · Cited by 453
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
Zviran, A., Schulman, R. C., Shah, M., Hill, S. T. K., Deochand, S., Khamnei, C. C., Maloney, D., Patel, K., Liao, W., Widman, A. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0915-3 · Cited by 434
Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., Schultz, A., Jin, M. C., Scherer, F., Garofalo, A., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00981-w · Cited by 374
Heitzer, E., Ulz, P., Belic, J., Gutschi, S., Quehenberger, F., Fischereder, K., Benezeder, T., Auer, M., Pischler, C., Mannweiler, S., et al. (2013) · Genome Medicine · doi:10.1186/gm434 · Cited by 357
Gale, D., Heider, K., Ruiz-Valdepenas, A., Hackinger, S., Perry, M., Marsico, G., Rundell, V., Wulff, J., Sharma, G., Knock, H., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.007 · Cited by 335
Self-citationIsaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms
Raczy, C., Petrovski, R., Saunders, C. T., Chorny, I., Kruglyak, S., Margulies, E. H., Chuang, H.-Y., Källberg, M., Kumar, S. A., Liao, A., et al. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt314 · Cited by 332
McDonald, B. R., Contente-Cuomo, T., Sammut, S.-J., Odenheimer-Bergman, A., Ernst, B., Perdigones, N., Chin, S.-F., Farooq, M., Mejia, R., Cronin, P. A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7392 · Cited by 305
Self-citationParkinson, C. A., Gale, D., Piskorz, A. M., Biggs, H., Hodgkin, C., Addley, H., Freeman, S., Moyle, P., Sala, E., Sayal, K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002198 · Cited by 297
Self-citationCanvas: versatile and scalable detection of copy number variants
Roller, E., Ivakhno, S., Lee, S., Royce, T., & Tanner, S. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw163 · Cited by 206
Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA
Shen, S. Y., Burgener, J. M., Bratman, S. V., & De Carvalho, D. D. (2019) · Nature Protocols · doi:10.1038/s41596-019-0202-2 · Cited by 199
McBride, D. J., Orpana, A. K., Sotiriou, C., Joensuu, H., Stephens, P. J., Mudie, L. J., Hämäläinen, E., Stebbings, L. A., Andersson, L. C., Flanagan, A. M., et al. (2010) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20815 · Cited by 196
ctDNA monitoring using patient-specific sequencing and integration of variant reads
Wan, J. C. M., Heider, K., Gale, D., Murphy, S., Fisher, E., Mouliere, F., Ruiz-Valdepenas, A., Santonja, A., Morris, J., Chandrananda, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8084 · Cited by 194
Self-citationStetson, D., Ahmed, A., Xu, X., Nuttall, B. R. B., Lubinski, T. J., Johnson, J. H., Barrett, J. C., & Dougherty, B. A. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00191 · Cited by 182
ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin
Sadeh, R., Sharkia, I., Fialkoff, G., Rahat, A., Gutin, J., Chappleboim, A., Nitzan, M., Fox-Fisher, I., Neiman, D., Meler, G., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00775-6 · Cited by 179
Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology
Kuderer, N. M., Burton, K. A., Blau, S., Rose, A. L., Parker, S., Lyman, G. H., & Blau, C. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4983 · Cited by 170
Straver, R., Sistermans, E. A., Holstege, H., Visser, A., Oudejans, C. B. M., & Reinders, M. J. T. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt992 · Cited by 166
Flach, S., Howarth, K., Hackinger, S., Pipinikas, C., Ellis, P., McLay, K., Marsico, G., Forshew, T., Walz, C., Reichel, C. A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01716-7 · Cited by 134
High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA
Chandrananda, D., Thorne, N. P., & Bahlo, M. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0107-z · Cited by 128
Plagnol, V., Woodhouse, S., Howarth, K., Lensing, S., Smith, M., Epstein, M., Madi, M., Smalley, S., Leroy, C., Hinton, J., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193802 · Cited by 94
Self-citationTsui, D. W. Y., Murtaza, M., Wong, A. S. C., Rueda, O. M., Smith, C. G., Chandrananda, D., Soo, R. A., Lim, H. L., Goh, B. C., Caldas, C., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201707945 · Cited by 89
Self-citationDetection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands
Cohen, J. D., Douville, C., Dudley, J. C., Mog, B. J., Popoli, M., Ptak, J., Dobbyn, L., Silliman, N., Schaefer, J., Tie, J., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00900-z · Cited by 89
Assessing aneuploidy with repetitive element sequencing
Douville, C., Cohen, J. D., Ptak, J., Popoli, M., Schaefer, J., Silliman, N., Dobbyn, L., Schoen, R. E., Tie, J., Gibbs, P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910041117 · Cited by 83
Almogy, G., Pratt, M., Oberstrass, F. C., Lee, L., Mazur, D., Beckett, N., Barad, O., Soifer, I., Perelman, E., Etzioni, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.29.493900 · Cited by 80
Kim, Y., Kim, Y.-H., Song, Y., Kim, H., Sim, H. W., Poojan, S., Eom, B. W., Kook, M., Joo, J., & Hong, K. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0292-5 · Cited by 73
Harris, F. R., Kovtun, I. V., Smadbeck, J. B., Multinu, F., Jatoi, A., Kosari, F., Kalli, K. R., Murphy, S. J., Halling, G. C., Johnson, S. H., et al. (2016) · Scientific Reports · doi:10.1038/srep29831 · Cited by 70
Liquid biopsies for residual disease and recurrence
Wan, J. C. M., Mughal, T. I., Razavi, P., Dawson, S., Moss, E. L., Govindan, R., Tan, I. B., Yap, Y. S., Robinson, W. A., Morris, C. D., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.001 · Cited by 50
Self-citationVollbrecht, C., Lehmann, A., Lenze, D., & Hummel, M. (2018) · Oncotarget · doi:10.18632/oncotarget.24908 · Cited by 37
Streubel, A., Stenzinger, A., Stephan-Falkenau, S., Kollmeier, J., Misch, D., Blum, T. G., Bauer, T. T., Landt, O., Ende, A. A., Schirmacher, P., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27183 · Cited by 20
Sadeh, R., Sharkia, I., Fialkoff, G., Rahat, A., Gutin, J., Chappleboim, A., Nitzan, M., Fox-Fisher, I., Neiman, D., Meler, G., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00853-3 · Cited by 12
Research works printed but not linked: 3
- Illumina Press Release Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health 2022 https://investor.illumina.com/news/press-release-details/2022/Illumina-Unveils-Revolutionary-NovaSeq-X-Series-to-Rapidly-Accelerate-Genomic-Discoveries-and-Improve-Human-Health/default.aspx
- Kurtz DM Soo J Co Ting Keh L Alig S Chabon JJ Sworder BJ Schultz A Jin MC Scherer F Garofalo A Enhanced detection of minimal residual disease by targeted sequencing of phased variants incirculating tumor DNA Nat Biotechnol 2021 b 39 1537 1547 34294911 PMC8678141 · DOI · Paper page
- Li Heng Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM arXiv:13033997v2 q-bioGN
Cited by
Use of ctDNA in early breast cancer: analytical validity and clinical potential
Panet, F., Papakonstantinou, A., Borrell, M., Vivancos, J., Vivancos, A. P., & Oliveira, M. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00653-3 · Cited by 132
Martínez-Castedo, B., Camblor, D. G., Martín-Arana, J., Carbonell‐Asins, J. A., García-Micó, B., Gambardella, V., Huerta, M., Roselló, S., Roda, D., Gimeno-Valiente, F., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.12.006 · Cited by 97
Marta, G. N., Monteforte, M., Agostinetto, E., Cinquini, M., Martins-Branco, D. A., Fontsa, M. L., Llombart‐Cussac, A., Cortés, J., Ignatiadis, M., Torri, V., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102390 · Cited by 86
Fusco, N., Venetis, K., Pepe, F., Shetty, O. A., Fariñas, S. C., Heeke, S., Burnier, J. V., Patton, S. J., Heitzer, E., Nigita, G., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100301 · Cited by 80
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Normanno, N., Morabito, A., Rachiglio, A. M., Sforza, V., Landi, L. M., Bria, E., Delmonte, A., Cappuzzo, F., & Luca, A. D. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00985-w · Cited by 78
Metadata
- Authors
- Santonja, A., Cooper, W. N., Eldridge, M. D., Edwards, P. A. W., Morris, J. A., Edwards, A. R., Zhao, H., Heider, K., Couturier, D., Vijayaraghavan, A., Mennea, P., Ditter, E., Smith, C. G., Boursnell, C., Manzano García, R., Rueda, O. M., Beddowes, E., Biggs, H., Sammut, S., Rosenfeld, N., Caldas, C., Abraham, J. E., & Gale, D.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Abraham, Jean E
- Gale, Davina
- ORCID
- Cooper, Wendy N
- Eldridge, Matthew D
- Edwards, Paul A W
- Morris, James A
- Edwards, Abigail R
- Zhao, Hui
- Heider, Katrin
- Couturier, Dominique‐Laurent
- Vijayaraghavan, Aadhitthya
- Mennea, Paulius
- Ditter, Emma‐Jane
- Smith, Christopher G
- Boursnell, Chris
- Manzano García, Raquel
- Rueda, Oscar M
- Beddowes, Emma
- Biggs, Heather
- Sammut, Stephen‐John
- Rosenfeld, Nitzan
- Caldas, Carlos
- Abraham, Jean E
- Gale, Davina
- Venue
- EMBO Molecular Medicine
- Published
- 2023-05-10
- Volume
- 15
- Issue
- 6
- Pages
- e16505-e16505
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC10245040
- OpenAlex
- W4376121423
- Cited by
- 66
- References
- 61
- Citations by year
- 2026: 16 · 2025: 36 · 2024: 12 · 2023: 2
- FWCI
- 8.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Addenbrooke's Charitable Trust, Cambridge University Hospitals (ACT 9800)
- AstraZeneca (A093777)
- Cancer Research UK (C507/A27657, CRUKE/14/048, C36857/A27548, C1287/A26886, C17918/A28870, EDDCPT\100013)
- EC | FP7 | Ideas | FP7 Ideas: European Research Council (337905)
- Mark Foundation For Cancer Research (C9685/A25177)
- NIHR | NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014)
- University of Cambridge | Cancer Research UK Cambridge Institute, University of Cambridge (A20240, C9545/A29580)
- Wellcome Trust (106566/Z/14/Z)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
- Keywords
- circulating tumor DNA, breast cancer, liquid biopsy, hybrid capture sequencing, multiplex PCR, structural variants, single nucleotide variants, somatic copy number alterations, minimal residual disease, allele fraction, assay sensitivity comparison
- MeSH terms
- Circulating Tumor DNA, Breast Neoplasms, Female, Humans, Mutation, Biomarkers, Tumor, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.